Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,980.50    19.00 (0.97%)
Bid:
1,979.50
Ask:
1,980.50
Spread: 1.00 (0.051%)
Market Cap: £79.33b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Replacement - Director/PDMR Shareholding

23 Jun 2025 17:50

RNS Number : 0548O
GSK PLC
23 June 2025
 

GSK plc (the 'Company')

 

The following amendment has been made to the Director/PDMR Shareholding announcement released on 23 June 2025 at 15.30 under RNS No 0150O.

 

1,350 Ordinary Shares were purchased by Lady Susan Symonds, PCA of Sir Jonathan Symonds (Non-Executive Chair).

 

All other details remain unchanged.

 

The full amended text is shown below.

 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Lady Susan Symonds

b)

Position/status

PCA of Sir Jonathan Symonds (Non-Executive Chair)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Purchase of 1,350 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.3550

1,350

d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-06-20

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Wendy Becker

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Purchase of 545 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.3550

545

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-06-20

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Elizabeth (Liz) McKee Anderson

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 258 ADSs

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$37.8958

 

258

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-06-20

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Charles Bancroft

b)

Position/status

Senior Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 2,021 ADSs

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$37.8958

2,021

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-06-20

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 258 ADSs

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$37.8958

258

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-06-20

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Anne Beal

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 257 ADSs

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$37.8958

257

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-06-20

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Dietz

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 257 ADSs

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$37.8958

257

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-06-20

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Jeannie Lee

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 258 ADSs

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$37.8958

258

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-06-20

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Vishal Sikka

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 889 ADSs

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$37.8958

889

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-06-20

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFZGZVVFDGKZM
Date   Source Headline
15th May 20257:00 amRNSTransaction in Own Shares
14th May 20257:00 amRNSGSK to acquire efimosfermin
14th May 20257:00 amRNSTransaction in Own Shares
13th May 20253:30 pmRNSDirector/PDMR Shareholding
13th May 202512:56 pmRNSUpdate on belrestotug development programme
13th May 20257:00 amRNSTransaction in Own Shares
12th May 20253:31 pmRNSBlock listing Interim Review
12th May 20257:00 amRNSTransaction in Own Shares
9th May 20257:00 amRNSTransaction in Own Shares
8th May 20255:15 pmRNSDirector/PDMR Shareholding
8th May 20253:30 pmRNSDirector/PDMR Shareholding
8th May 202511:15 amRNSLinerixibat GLISTEN pIII trial data at EASL
8th May 20257:00 amRNSTransaction in Own Shares
7th May 20256:22 pmRNSResult of AGM
7th May 20257:00 amRNSTransaction in Own Shares
6th May 20257:00 amRNSTransaction in Own Shares
2nd May 20257:00 amRNSTransaction in Own Shares
1st May 20253:30 pmRNSDirector/PDMR Shareholding
1st May 20253:00 pmRNSTotal Voting Rights
1st May 20257:00 amRNSNucala MATINEE data in COPD published in NEJM
1st May 20257:00 amRNSTransaction in Own Shares
30th Apr 20257:05 amRNSTransaction in Own Shares
30th Apr 20257:00 amRNS1st Quarter Results
29th Apr 20257:00 amRNSTransaction in Own Shares
28th Apr 20257:00 amRNSTransaction in Own Shares
25th Apr 20257:00 amRNSTransaction in Own Shares
24th Apr 20257:00 amRNSTransaction in Own Shares
23rd Apr 20257:00 amRNSTransaction in Own Shares
22nd Apr 20257:00 amRNSTransaction in Own Shares
17th Apr 20254:13 pmRNSBlenrep licensed by UK MHRA
17th Apr 20253:30 pmRNSDirector/PDMR Shareholding
17th Apr 20257:10 amRNSArexvy now ACIP recommended for 50-59 at risk
17th Apr 20257:05 amRNSGSK 5-in-1 meningitis vaccine recommended in US
17th Apr 20257:00 amRNSTransaction in Own Shares
16th Apr 20257:00 amRNSTransaction in Own Shares
15th Apr 20253:30 pmRNSDirector/PDMR Shareholding
15th Apr 20257:00 amRNSTransaction in Own Shares
14th Apr 20257:00 amRNSTransaction in Own Shares
11th Apr 20253:30 pmRNSDirector/PDMR Shareholding
11th Apr 20257:00 amRNSTransaction in Own Shares
10th Apr 20257:00 amRNSTransaction in Own Shares
9th Apr 20257:00 amRNSTransaction in Own Shares
8th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSTransaction in Own Shares
4th Apr 20257:00 amRNSTransaction in Own Shares
3rd Apr 20257:00 amRNSTransaction in Own Shares
2nd Apr 20257:00 amRNSTransaction in Own Shares
1st Apr 20253:30 pmRNSTotal Voting Rights
1st Apr 20257:00 amRNSTransaction in Own Shares
31st Mar 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.